Rebus Holdings, Inc. (RBSH)
OTCMKTS: RBSH · Delayed Price · USD
0.0001
0.00 (0.00%)
Apr 11, 2024, 2:46 PM EDT - Market open
Company Description
Rebus Holdings, Inc., together with its subsidiaries, focuses on the research and development of precision therapeutics for the treatment of cancer.
Its lead asset is RT-AR001, an adenosine receptor antagonist for tumor infiltration and enhanced outcomes when administered intra-tumorally.
Rebus Holdings, Inc. was incorporated in 2003 and is based in Westlake Village, California.
Rebus Holdings, Inc.
| Country | United States |
| Founded | 2003 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1 |
| CEO | Raul Silvestre Esq. |
Contact Details
Address: 2629 Townsgate Rd, Suite 215 Westlake Village, California 91361 United States | |
| Phone | (210) 479-8112 |
| Website | rebus-corp.com |
Stock Details
| Ticker Symbol | RBSH |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001421204 |
| CUSIP Number | 75619J103 |
| ISIN Number | US75619J1034 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Raul Silvestre Esq. | Chief Executive Officer, Chief Financial Officer, President, Principal Accounting Officer and Director |
| Dr. John T. Isaacs Ph.D. | Co-Founder, Chairman of Scientific Advisory Board and Chief Scientific Advisor |
| Dr. Samuel R. Denmeade M.D. | Co-Founder, Chief Clinical Advisor and Member of Scientific Advisory Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 21, 2023 | 10-Q | Quarterly Report |
| Aug 14, 2023 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| May 15, 2023 | 10-Q | Quarterly Report |
| Mar 31, 2023 | 10-K | Annual Report |
| Jan 10, 2023 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 21, 2022 | 10-Q | Quarterly Report |
| Nov 16, 2022 | 8-K | Current Report |
| Nov 14, 2022 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| Oct 13, 2022 | 8-K | Current Report |
| Aug 12, 2022 | 10-Q | Quarterly Report |